Preclinical Development & Co-Founder
John W. Ferkany, PhD
was invited to join Oread, Inc. in 1996 as Director of the Division
of Pharmacology. Having successfully organized and staffed that
group while building it to a multi-million-dollar/year revenue generating
operation, he was invited to join the Drug Development Program Management
team in 1998.
As a Director,
Program Management, the incumbent was responsible to design, coordinate,
manage and execute multi-disciplinary IND programs encompassing
regulatory affairs, chemistry and manufacturing controls, safety
pharmacology, toxicology, manufacturing and packaging of clinical
trials materials, as well as preparation of regulatory documents.
He gained a thorough knowledge of the preclinical drug development
process including ICH, FDA, OECD and MHW regulatory requirements.
At the time of his departure from Oread subsequent to a corporate
restructuring, he had successfully guided multiple IND programs
Prior to his
experience at Oread, Dr. Ferkany served as a Vice President and
Chief Technical Officer of Oceanix Biosciences Corporation, a privately
held biotechnology company located in Hanover, MD. In 1993 he participated
in the acquisition of NovaScreen, an international Contract
Research Organization specializing in early stage drug discovery,
from SciosNova. At the time of the purchase, NovaScreen had
posted 4 successive years of declining revenues. Nova Pharmaceutical
Corporation from July 1984 to late 1992 employed Dr. Ferkany. During
this period, Dr. Ferkany supervised up to 35 Ph.D. and technical
scientists including medicinal chemists, molecular biologists, pharmacologists
and behavioral scientists. .
educational background includes a B.S. in Zoology (1976) from the
University of Michigan, a doctoral degree in Biomedical Sciences
(1980) from the University of Texas at Houston, and a Masters in
Administrative Sciences (1991) awarded from the Johns Hopkins University
in Baltimore, Maryland where the incumbent received the Edward J.
Stegman Award for Excellence having graduated with a perfect record.
is a member of the editorial board of the Journal of Pharmacology
and Experimental Therapeutics and of Current Protocols in Pharmacology,
of 4 scientific Societies, and has published extensively in the
field of central nervous system disorders as well as on current
methods in drug discovery. He is a consensus manager dedicated to
team concepts, "coaching" and the advancement of subordinates.